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Introduction
Every year, over 1.5 million patients are admitted to hos-
pitals after presenting to the Emergency Department (ED) 
with acute chest pain. Only a small percentage of these ad-
mitted patients have Acute Coronary Syndromes (ACSs) 
and the vast majority of them are discharged with non-
cardiac diagnoses. Acute chest pain is an important and 
frequently occurring symptom in patients. Chest pain is 
often a sign of ischemic heart disease, although gender, 
age, and comorbidity may modify how acute Coronary 
Heart Disease (CHD) presents itself within the individ-
ual patient. Acute chest pain may indicate a potentially 
life-threatening situation, but it is also commonly ac-
knowledged that a wide variety of differential diagnosis 
exists, many with lower health impacts and less serious 
potential effects (1).
Chest pain caused by ACS is an important factor in in-
creasing the number of hospitalizations. So it is necessary 
to weight the costs and benefits of accurate diagnosis to 
determine the optimal strategy for MI diagnosis (2). 
After establishing Myocardial Infarction (MI), then 
the risk of future adverse events can be determined us-
ing  biomarkers of ischemia or inflammation, exercise 
Electrocardiography (ECG) or Computed Tomographic 
Coronary Angiography (CTCA), along with antithrom-
botic treatment or coronary intervention which are used 
to reduce the risk of adverse outcomes in individuals with 
positive tests (2). ACS is usually associated with chest pain 
and must be differentiated from other common causes 
of chest pain such as muscular pain, gastro-oesophageal 
pain and anxiety. As clinical assessment is unreliable and 
the electrocardiogram may be normal in the presence ofA 
CS, establishing such differentiation is difficult. Patients 
with suspected ACS constitute a large and varied popula-
tion; many of them have not ACS or CAD, but have non-
cardiac causes for their chest pain. So ACS and Coronary 
Artery Disease (CAD) must be carefully identified to 
establish the best interventions (3). Determining the op-
timal strategy involves weighing the benefits of reducing 
adverse events against costs of additional investigation 
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Abstract
Acute chest pain is an important and frequently occurring symptom in patients. 
Chest pain is often a sign of ischemic heart disease. Chest pain due to suspected 
Acute Coronary Syndrome (ACS) is responsible for a large and increasing number of 
hospital attendances and admissions.  Current practice for suspected ACS involves 
troponin testing 10–12 hours after symptom onset to diagnose Myocardial Infarction 
(MI). Patients with a negative troponin can be investigated further with Computed 
Tomographic Coronary Angiography (CTCA) or exercise Electrocardiography (ECG).
A review of cardiac biomarkers as screening test in acute chest pain over 15 years 
was conducted. Separate searches were under taken for  biomarkers. We Searched 
electronic databases up to 2004-2014, reviewed citation lists and contacted 
experts to identify diagnostic and prognostic studies comparing a relevant index 
test (biomarker, CTCA or exercise ECG) to the appropriate reference standard. We 
classified studies to two part early rise biomarkers, high sensitivity biomarkers.
Conclusion: Although presentation troponin has suboptimal sensitivity, 
measurement of a 10-hour troponin level is unlikely to be cost-effective in most 
scenarios compared with a high sensitivity presentation troponin. Measurement of 
cardiac troponin using a sensitive method was the best test for the early diagnosis 
of an Acute Myocardial Infarction (AMI). Measurement of myoglobin or Creatine 
Kinase-MB (CK-MB) in addition to a sensitive troponin test is not recommended. 
Heart-type Fatty Acid-Binding Protein (H-FABP) shows promise as an early marker 
and requires further study.
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and treatment (4).
Methods
A review of cardiac biomarkers as screening test in acute 
chest pain over 15 years was conducted. Separate searches 
were done for biomarkers too. We searched electronic da-
tabases from 2000 up to 2014, reviewed citation lists, and 
contacted experts to identify diagnostic and prognostic 
studies comparing a relevant index test (biomarker, CTCA 
or exercise ECG) to the appropriate reference standard 
[MI according the universal definition, CAD on Invasive 
Coronary Angiography (ICA) or Major Adverse Cardiac 
Events (MACE)] in patients presenting with suspected 
ACS. We classified studies into two parts. They encompass 
early rise biomarkers, and high sensitivity biomarkers. 
Early risk biomarkers 
Many systematic reviews have been conducted to inves-
tigate the diagnostic (5) and prognostic (6) accuracy of 
troponin testing in suspected ACS (7). Other systematic 
reviews also are done to determine the diagnostic accu-
racy of troponin, CK, CK-MB, and myoglobin (8). The 
result shows that troponin has the highest accuracy for 
MI. The standard diagnostic method for suspected ACS 
is to measure troponin levels 10-12 hours after symptoms 
onset. There are alternative and effective biomarkers to 
improve the diagnostic accuracy of troponin assay for MI 
and it forms the reference standard (4). However; alterna-
tive biomarkers may have a role in targeting two limita-
tions in troponin measurement (2). First, because of the 
limited early sensitivity of troponin, there is a potential 
for biomarkers with better early sensitivity for MI and care 
improvement. Second, although a negative 10-12-hour 
troponin assay stratifies patient to a low risk of adverse 
outcome, this does not equate to a negligible risk. Thus 
alternative biomarkers can have an important role in de-
termining the further risk of patients. The relative insen-
sitivity of the early generation of cardiac troponin assays 
indicates that much information can be provided about 
patients with acute chest pain by exploring the small cyto-
plasmic proteins which leak trough the ischemic myocar-
dial cell membrane. Myoglobin, a single–chain globular 
protein, could be an early marker for MI. It is consisted of 
a haem prosthetic group and is the primary oxygen stor-
age protein in muscle tissues (2). 
Finding markers that are realized when myocardial isch-
emia occurs, is an alternative approach. A form of human 
serum albumin is ischemia-modified albumin, in which 
ischemia has an effect on N-terminal amino acids in or-
der to bind transition metals. Fatty acid-binding proteins 
are relatively small proteins, of 126-137 amino acids in 
length. These proteins are present in tissues such as heart, 
intestine, and liver that have active fatty acid metabolism. 
Heart-type Fatty Acid-Binding Protein (H-FABP), a myo-
cardial isoform, is predominantly in heart. However; it has 
been seen in other tissues such as skeletal muscles and dis-
tal tubal cells of the kidney (2). 
Myoglobin
Myoglobin (with molecular weight of 16.7 KDa) is a sin-
gle-chain globular protein that consists of a haem pros-
thetic group. Myoglobin is the primary Oxygen-carrying 
pigment in muscle tissues. It is also found in cytoplasm 
and considering its low molecular weight, it can be re-
leased earlier than other cytoplasmic biomarkers after 
myocyte necrosis. In some studies it is proposed that myo-
globin measures can be an early marker for AMI (9-11). 
Comparing Myoglobin measures with kinetics and car-
diospecificity of other markers has shown that myoglobin 
measurement can be used in combined with other cardiac 
biomarkers in a panel for early diagnosis of AMI (12-14), 
especially in point of care testing (15).
Creatine kinase MB isoenzyme
Creatine Kinase-MB (CK-MB) isoenzyme is the more 
cardiac-specific isoenzyme of CK and is present in the cy-
toplasm and forms 5-50% of the CK of the myocardium, 
which is one of the earliest cardiac biomarkers used for 
the biochemical detection of an AMI (16-18). Mass as-
says which are designed and developed for CK-MB are 
automated and form the basis of current methodology 
(19-21). One of the most established biomarkers of AMI 
is the measurement of CK-MB mass and is still recognized 
in the universal definition of MI. The advantage of this 
method is an earlier rise of CK-MB, compared to cardiac 
troponin (22).
Fatty Acid-binding Protein (FABP) and other early 
phase reactive protein
FABPs are relatively small proteins (15 DKa) that consist 
of 126-137 amino acids. These proteins are present in tis-
sues such as heart, liver, and intestine which have an active 
fatty acid metabolism. They reversibly bind long chain fat-
ty acids so can enhance their intracellular translocation. 
Nine types of FABP have been identified, each has a spe-
cific pattern of tissue distribution and their intracellular 
half-time is 2-3 days (23). H-FABP, an isoform of myocar-
dial, is found predominantly in the heart, but also is pres-
ent in other tissues such as skeletal muscle and the distal 
tubal cells in the kidney. The potential role of H-FABP 
in diagnosing the MI has been investigated by a number 
of studies (24-26). H-FABP may be an early cytoplasmic 
marker of myocardial ischemia and myocardial injury (2).
Other markers of the atherothrombotic process, in ad-
dition to the measurement of cardiac troponin, can be 
measured and allow earlier diagnose. Markers of athero-
matous plaque destabilization or rupture have been pro-
posed, including inflammatory markers [C-Reactive Pro-
tein (CRP), interleukin 6, interleukin 33/ST2 and Growth 
Differentiation Factor 15 (GDF-15)] and biomarkers 
that are considered to be associated with the plaque it-
self [Myeloperoxidase (MPO), matrix metalloproteinases 
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and Pregnancy-Associated Plasma Protein A (PAPP-A)]. 
Markers of myocardial dysfunction such as B-type natri-
uretic peptide (BNP) N-terminal pro-B-type natriuretic 
peptide (NT-pro-BNP), copeptin and adrenomedullin 
also can be used alternatively. A systematic review of 22 
novel biomarkers such as CRP, MOP, BNP and H-FABP 
(8) has shown that the evidences to support the usefulness 
of these biomarkers in ED assessment of suspected ACS 
are insufficient. Along with this analysis, further studies 
have been conducted to estimate the diagnostic and prog-
nostic accuracy of alternative biomarkers. However; other 
researches have shown that modern troponin assays have 
much improved the early sensitivity. Thus; the aim of this 
study is to investigate the role of early biomarkers in iden-
tifying MI before 10-12 hours, and the role of alternative 
biomarkers in providing additional risk stratification for 
troponin-negative patients with suspected ACS (2).
 
High-sensitivity troponin and alternative biomarkers 
The cardiac troponins from part of the cardiac contractile 
apparatus, the troponin–tropomyosin complex, and com-
prise three troponins [troponin C, troponin I (TnI) and 
troponin T (TnT)] plus tropomyosin (1-30). 
Some immunoassays have been developed to measure 
TnT and TnI, as they have unique structures. Preliminary 
studies have demonstrated that the measurement of car-
diac troponin is both more sensitive and more specific for 
myocardial injury than biomarkers used previously. TnT 
or TnI is now the recommended biomarkers for MI. The 
original redefinition of acute MI suggested that the ana-
lytical imprecision of the assay should allow measurement 
with a low analytical imprecision within the reference 
interval of the assay. This quality specification is not met 
by the assays available in the past years and this causes 
to increasing improvement in assay quality until current 
generation of sensitive troponin assays has been formed. 
Sensitive troponin assays can measure troponin in healthy 
individuals with a high degree of analytical imprecision, 
typically <10% imprecision at the 99% of a reference pop-
ulation (1-30). 
In addition to meeting the quality specification stipulated 
in the universal definition of acute MI, the new sensitive 
assays can detect myocardial injury substantially earlier 
than the previous generation of assays. Progressive im-
provement in the analytical performance in troponin as-
says has demonstrated that, the analytical performance 
of second—and third generation assays—is   already be-
ginning to outstrip other markers of myocardial injury 
such as myoglobin and CK-MB (27,28). Also, studies 
on new high-sensitivity assays have demonstrated that 
they are superior to all of the conventional markers of 
myocardial injury.
Troponin 
The two main subjects that will be discussed in this sec-
tion are as follows:
1) The use of troponin and other biomarkers to diagnose 
MI when hospitalization. 
2) The use of other biomarkers, exercise ECG and CTCA 
to risk-stratify patients with acute chest pain and a nega-
tive troponin. 
Troponin should be measured at least 10-12 hours after 
the onset of symptoms using the 99 high risk of a diagnos-
tic threshold. It can be helpful in diagnosing MI accurately 
and identifying patients with high risk of adverse outcome. 
It also helps patients benefit from hospital treatment. 
However, patients waiting for delayed testing are currently 
detained in hospital until 10-12 hours after symptoms 
onset (29). This delay results in additional health services 
costs and causes inconvenience for patients. An earlier di-
agnostic assessment could allow earlier hospital discharge, 
thus decreasing costs, but would risk missed MI opportu-
nity to benefit from treatment if sensitivity were subopti-
mal. High-sensitivity troponin assays, either alone or in 
combination with other biomarkers, can be used to diag-
nose MI before 10-12 hours.  But the cost savings of this 
approach must be weighted against the missed benefit, in 
other words, the additional benefits of 10-12 hours tropo-
nin sampling need to be weighted against the additional 
costs (2). Considering that the risk is not negligible, it will 
be beneficial to measure other biomarkers that can predict 
increased risk independent of troponin levels. Troponin-
negative patients may also be investigated by exercise ECG 
or CTCA for identifying those with CAD and the patients 
with an increased risk of adverse outcome may benefit 
from coronary intervention and medical treatment. So, 
there is a necessity to estimate the diagnostic accuracy of 
exercise ECG and CTCA for CAD, and the prognostic ac-
curacy of exercise ECG and CTCA for MACEs and the 
cost effectiveness of using exercise ECG or CTCA in se-
lecting patients who need hospitalization (1-30).
 
Description of diagnostic studies of presentation 
troponin 
Diagnostic studies of presentation TnI and TnT have been 
identified in this research. Two studies that evaluated TnI 
and TnT, applied variable inclusion and exclusion criteria 
and in several studies patients with a diagnostic ECG were 
excluded. Prevalence of MI varies from 5–73% and was 
relatively high (2), suggesting that patients cohort may 
have been affected by implicit selection processes. Time 
delay from symptoms to presentation varies from 1.2 
(mean) hours to 6 hours (median). Data showed that sev-
eral studies have used different diagnostic thresholds for 
the index test; however, the data in this study is based on 
the 99th percentile, 10% Coefficient of Variation (CV) and 
Limit of Detection (LoD). In all of these studies, the uni-
versal definition of MI  was used as the reference standard 
and in most of them some form of adjunction was also 
used – taking into account the results of tropinin testing. 
In most cases, the troponin used for the reference stan-
dard was a standard (i.e. not high sensitivity) assay using 
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the 10% CV or 99th percentile as a diagnostic threshold. 
However, in Christ et al study a reference standard based 
on High-sensitivity TnT (HsTnT) alongside a reference 
standard based on the standard assay was used (30). The 
data in this study is collected based on the standard assay 
reference standard. The studies were generally high qual-
ity, and the lower-quality studies were excluded by our 
selection criteria. Presentation troponin measurement is 
obviously not independent of a troponin-based reference 
standard, so the focus in the assessment of verification 
bias is on whether or not the index and reference stan-
dard troponin were measured on different samples. There 
is some uncertainty about whether index and reference 
standard tests were assessed blind or not. This is unlikely 
to have an influence on reporting the index test as in most 
cases this is done by a mechanized process producing a 
quantitative result (1-30).
Description of diagnostic studies of other biomarkers
Diagnostic studies of other biomarkers have been iden-
tified in this study too. The prevalence of MI was lower 
than the studies of troponin, H-FABP and myoglobin, and 
varied from 5% to 29%. The median time from symptom 
onset to sampling varied from 2 to 4.5 hours. Most of the 
studies used a modern troponin assay with an acceptable 
threshold for the reference standard (2).
Diagnostic studies of biomarkers in combination with 
troponin: some studies have compared the analyses of the 
sensitivity and specificity of biomarkers in combination 
with troponin alone. We did not use any meta-analysis in 
our research as no combination was evaluated (2). 
Troponin and the alternative biomarker are combined and 
classified as positive if either test is positive. However, the 
combination is classified as positive only if both tests are 
positive. Thus, in most studies the combination had high-
er sensitivity and lower specificity than troponin alone, 
whereas the combinations tested had lower sensitivity and 
higher specificity than troponin alone (1-29). The results 
of these studies suggested that combining troponin with 
another biomarker at presentation, with elevation of ei-
ther biomarker producing a positive test, results in signifi-
cantly improved sensitivity but with a loss in specificity 
that can be substantial. In none of these analyses a high-
sensitivity troponin assay was used. The results of the tro-
ponin meta-analysis indicated that a similar enhancement 
in sensitivity at the expense of specificity can be achieved 
if a lower threshold for troponin positivity is used (29).
Diagnostic accuracy of presentation biomarkers for MI
A large number of studies have estimated the accuracy 
of troponin at presentation for diagnosing MI, compared 
with a reference standard based on the universal defini-
tion using delayed troponin testing. The accuracy of tro-
ponin at presentation for diagnosing MI has been esti-
mated in a large number of studies and the results were 
compared either a reference standard that is based on the 
universal definition using delayed troponin testing. In 
many of these studies the troponin assay, used as the index 
or reference standard, was inadequate and also, because of 
the threshold, comparing and synthesizing data from dif-
ferent studies  was difficult (1-30).
The differences in estimates of sensitivity and specificity 
for different assays indicate that there are differences in 
study methods and populations, however one can con-
clude that using a lower threshold for positivity and high-
sensitivity assay can improve sensitivity at the expense of 
specificity. It is unknown that whether the loss of specific-
ity indicates the expected loss of specificity, as seen where 
the threshold for positivity is lowered for an imperfect 
test, or whether the apparent False-Positives (FPs) may 
indeed be True-Positives (TPs), which are misclassified by 
an inadequate reference standard. Further data provided 
in this study can help to determine whether the estimates 
of sensitivity for troponin at presentation are lower when 
compared with a high-sensitivity reference standard. 
The results of this study suggest that high-sensitivity as-
says have sufficient sensitivity at presentation to identify 
most cases of MI that would subsequently be identified by 
a standard 10-hour troponin test, but these estimates are 
not completely reliable and a significant proportion with 
MI will be missed by presentation troponin testing. Con-
ducting 10-hour troponin testing mostly depends on the 
costs and benefits of detecting additional cases and it can 
be explored in detail in the economic analysis (1-30).
Conclusion
Increasing use of high-sensitivity troponin assays results 
in many advantages and facilities service provision. More 
positive results can be obtained by high-sensitivity assays 
than standard assays, but the prognostic significance of 
these additional positive cases is not clearly known. Some 
Services are provided, considering the hypothesis that pa-
tients with a positive troponin have an increased risk of 
adverse outcome and further investigation and interven-
tion will be useful for these groups. This assumption may 
not be applicable for some patients in which their tropo-
nin elevation has a small increase or shows no significant 
increase in risk. Widespread use of high-sensitivity tropo-
nin testing can be potent to significantly increase demand 
for cardiology services. However further research is need-
ed to determine how and whether this demand should be 
met (1-29). (Early rise biomarker with low sensitivity).
Test for the early diagnosis of an AMI is the measure-
ment of cardiac troponin by using a sensitive method. 
Although diagnosis 90 minutes from admission was safe 
but 100% diagnostic sensitivity was not obtained at that 
time point and more research is necessary to determine 
the optimal earliest time point when an acceptable diag-
nostic sensitivity can be achieved. We do not suggest mea-
suring myoglobin or CK-MB as well as a sensitive tropo-
nin test. H-FABP is promising in terms of an early marker 
and needs more study. The measurement of copeptin is 
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not recommended as a routine test in patients presenting 
with acute chest pain. Ten-hour troponin testing seems to 
be cost-effective in comparison to rapid rule-out strategies 
only if patients can be discharged as soon as a negative 
result is available (29).
Ethical issues
Not applicable.
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